主管单位:中华人民共和国
国家卫生健康委员会
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
单位:中国人民解放军总医院第一医学中心麻醉科,北京100853
英文单位:Department of Anesthesiology the First Medical Center Chinese PLA General Hospital Beijing 100853 China
英文关键词:Cardiogenicshock;Newbiomarkers;Riskassessment;Prognosticprediction
心源性休克(CS)病情进展快、死亡率高,需要快速识别和处理高风险患者,血浆生物标志物的检测有助于CS患者的早期风险识别,从而优化治疗措施。近年来,新的CS生物标志物在休克进展、病程监测和死亡风险预测中的作用受到临床关注,这些标志物包括与炎症、免疫、内皮功能相关的标志物以及基于蛋白质组学筛选的标志物等。本文对几种CS新型生物标志物在休克风险评估和预后预测中的作用研究进展进行综述。
Cardiogenic shock (CS) is characterized by rapid progression and high mortality, which requires rapidly identification and management of the high-risk patients. The detection of plasma biomarkers is helpful for early risk identification of CS patients, so as to optimize treatment measures. In recent years, the role of new CS biomarkers in shock progression, disease course monitoring and death risk prediction has attracted clinical attention. These biomarkers include markers related to inflammation, immunity, endothelial function, and markers based on proteomics screening. This article reviews the research progress of several novel biomarkers of CS in shock risk assessment and prognosis prediction.
copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。